Brett N. Tomson

TL;DR: FGFR aberrations are common in a wide variety of cancers, with the majority being gene amplifications or activating mutations, and data suggest that FGFR inhibition could be an important therapeutic option across multiple tumor types.

TL;DR: A framework of patient-partnered research allows patients with angiosarcoma to share their samples and clinical records securely to accelerate molecular characterization of tumors and identification of therapeutic approaches, demonstrating that empowering patients to directly participate in research can overcome barriers in rare diseases and can enable discoveries.

TL;DR: A patient-partnered research approach using online engagement to discover the etiology and potential therapies for angiosarcoma patients demonstrates that empowering patients to directly participate in research can overcome barriers in rare diseases and enable biological and clinical discoveries.

TL;DR: Each individual with malignant mesothelioma harbored a unique set of genomic aberrations, suggesting that NGS-based profiling of patients will be needed if patients are to be optimally matched to cognate treatments.

TL;DR: Merkel cell carcinomas were characterized by multiple distinct aberrations that were unique in the majority of analyzed cases, providing a framework for investigating tailored combinations of matched therapies in Merkel cell carcinoma patients.